Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) posted its earnings results on Thursday. The biotechnology company reported ($5.38) EPS for the quarter, missing analysts' consensus estimates of ($5.28) by ($0.10), Zacks reports. Cidara Therapeutics had a negative net margin of 289.05% and a negative return on equity of 69.64%.
Cidara Therapeutics Trading Down 2.9 %
Shares of CDTX stock traded down $0.70 during trading hours on Monday, hitting $22.97. The company's stock had a trading volume of 59,899 shares, compared to its average volume of 59,647. The stock has a market cap of $161.83 million, a PE ratio of -0.90 and a beta of 0.88. Cidara Therapeutics has a 12-month low of $10.00 and a 12-month high of $28.42. The company has a 50 day moving average of $22.52 and a 200 day moving average of $17.51.
Analyst Ratings Changes
A number of equities research analysts have commented on CDTX shares. Needham & Company LLC reiterated a "buy" rating and issued a $35.00 price target on shares of Cidara Therapeutics in a research note on Friday. Cantor Fitzgerald upgraded shares of Cidara Therapeutics to a "strong-buy" rating in a research note on Wednesday, February 5th. WBB Securities boosted their target price on shares of Cidara Therapeutics from $40.00 to $45.00 and gave the stock a "strong-buy" rating in a research report on Thursday, December 5th. HC Wainwright raised their price target on shares of Cidara Therapeutics from $24.00 to $35.00 and gave the stock a "buy" rating in a report on Monday. Finally, Royal Bank of Canada initiated coverage on shares of Cidara Therapeutics in a research note on Friday, December 13th. They set an "outperform" rating and a $34.00 price objective for the company. One analyst has rated the stock with a sell rating, four have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $36.40.
Read Our Latest Report on Cidara Therapeutics
About Cidara Therapeutics
(
Get Free Report)
Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
Featured Articles
Before you consider Cidara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cidara Therapeutics wasn't on the list.
While Cidara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
